Imugene (ASX:IMU) received a notice of allowance from the US Patent and Trademark Office for patent application number 16/637,909, protecting its oncolytic virotherapy CF33-CD19 and its combination with CD19 targeting CAR T cell therapies, according to a Wednesday filing with the Australian bourse.
The patent offers protection for the method of composition and method of use through to Aug. 10, 2038, the filing said.
Shares fell past 7% in midday trade Wednesday and hit their lowest since January 2018.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.